# Handoff: Cancer Module Abstract Extraction — 2026-06-03

**Session Status:** COMPLETE
**Final Extraction Depth:** 97% (99/102 cards at abstract+ level)

## Quick Verification

```bash
# Final extraction depth counts
grep -l "extraction_depth: abstract" raw/papers/src-cancer-*.md | wc -l  # 93
grep -l "extraction_depth: full" raw/papers/src-cancer-*.md | wc -l     # 6
grep -l "extraction_depth: partial" raw/papers/src-cancer-*.md | wc -l  # 3 (not PubMed indexed)
```

## What Was Done This Session

### Cards Upgraded (16 cards total)

**Batch 1 (5 cards):**
| Card ID | PMID | Year | Key Finding |
|---------|------|------|-------------|
| src-cancer-027 | 6690068 | 1984 | Steroid receptor profiles in canine/feline mammary tumors |
| src-cancer-053 | 5694272 | 1968 | Alameda County cancer morbidity survey (no abstract) |
| src-cancer-066 | 5575715 | 1971 | FeLV epidemiology commentary (no abstract) |
| src-cancer-069 | 20412586 | 2010 | 28% IEL prevalence in FMC, ER/PR-negative model |

**Batch 2 (4 cards):**
| Card ID | PMID | Year | Key Finding |
|---------|------|------|-------------|
| src-cancer-071 | 29090969 | 2017 | 95% podoplanin+ in feline SCC |
| src-cancer-072 | 36342778 | 2022 | FA-SAT ncRNA biomarker correlations |
| src-cancer-073 | 38378135 | 2024 | mPGES1/p16 in FOSCC vs HOSCC |
| src-cancer-074 | 30078599 | 2018 | 92% CD3+ T cells, 57% Treg in FOSCC |

**Batch 3 (4 cards):**
| Card ID | PMID | Year | Key Finding |
|---------|------|------|-------------|
| src-cancer-077 | 15308173 | 2004 | BNCT in 3 feline head/neck patients |
| src-cancer-078 | 4346020 | 1972 | FMC morphology/biology (no abstract) |
| src-cancer-076 | — | — | Not PubMed indexed (SCIRP journal) |
| src-cancer-079 | — | — | Not PubMed indexed (DOI verified) |

**Batch 4 (6 cards):**
| Card ID | PMID | Year | Key Finding |
|---------|------|------|-------------|
| src-cancer-080 | 31661586 | 2020 | MCT1/MCT4 inhibitor MD-1 in FOSCC |
| src-cancer-081 | 36010653 | 2022 | TILs/TAMs in 73 FMC, CD8+ prognostic |
| src-cancer-082 | 224237 | 1979 | FeLV pathogenesis (no abstract) |
| src-cancer-083 | 20193912 | 2010 | 80% FMC malignant, management review |
| src-cancer-084 | 6258787 | 1980 | FeLV age-dependent susceptibility |
| src-cancer-085 | 29359611 | 2018 | PDT 84% response, 40mo median OS |

**Session 2 Batch (9 cards):**
| Card ID | PMID | Year | Key Finding |
|---------|------|------|-------------|
| src-cancer-086 | 204584 | 1978 | FeLV subgroups: 58% FeLV-AB in lymphosarcoma, FeLV-C only in disease |
| src-cancer-087 | 6254637 | 1980 | FeLV humoral immunity (no abstract) |
| src-cancer-088 | 30012106 | 2018 | CXCR4/CXCL12 in FMC metastasis, HER2+ distinct pattern |
| src-cancer-089 | 6291969 | 1982 | FeLV review by Essex (no abstract) |
| src-cancer-090 | 21282070 | 2012 | AKT activation prognostic marker for FMC |
| src-cancer-091 | 34437486 | 2021 | FMC biomarkers and targeted therapies review |
| src-cancer-092 | 34579716 | 2021 | TK1 serum biomarker for cancer diagnosis |
| src-cancer-094 | 4997847 | 1971 | Transmissible feline fibrosarcoma, viral origin (no abstract) |
| src-cancer-096 | 1327427 | 1992 | FeLV pathogenesis of neoplastic disease review (no abstract) |
| src-cancer-097 | 32645884 | 2020 | Genome-wide microarray platform for feline cancers |
| src-cancer-098 | — | — | Duplicate of src-cancer-091 |
| src-cancer-100 | 34438778 | 2021 | FMCm high drug resistance vs MCF-7 |

**Final Batch (4 cards):**
| Card ID | PMID | Year | Key Finding |
|---------|------|------|-------------|
| src-cancer-093 | 40839607 | 2025 | Phosphoproteomic profiling FMC, grading biomarkers |
| src-cancer-099 | PMC2034422 | 2007 | Book review: Geriatric Oncology (not primary research) |
| src-cancer-101 | 33809013 | 2021 | TFR-1 expression, doxorubicin-loaded HFn nanocages |
| src-cancer-102 | 189052 | 1977 | FeLV horizontal transmission: 85% from gsa+ cats |

### All Cards Processed

All 102 source cards have been processed.

## Final State

### Extraction Depth Breakdown
```
Cancer module: 102 total source cards
├── Full extraction:     6 cards (6%)  - deep extraction with structured data
├── Abstract extraction: 93 cards (91%) - PubMed abstract + Source Check table
├── Partial extraction:  3 cards (3%)  - not PubMed indexed, DOI verified
└── Total at abstract+ depth: 99/102 (97%)
```

### Not PubMed Indexed (remain at partial)

| Card ID | Reason |
|---------|--------|
| src-cancer-030 | Book chapter |
| src-cancer-076 | SCIRP journal (not indexed) |
| src-cancer-079 | DOI verified, not in PubMed |

### Special Cases

| Card ID | Status |
|---------|--------|
| src-cancer-098 | Duplicate of src-cancer-091 |
| src-cancer-099 | Book review (not primary research) |

## Session Metrics

**Session 1:**
- Cards upgraded: 16 (10 with abstracts, 3 historical/no abstract, 3 not indexed)
- API cost: $0 (PubMed E-utilities only)

**Session 2:**
- Cards upgraded: 12 (9 with abstracts, 4 historical/no abstract, 1 duplicate)
- API cost: $0 (PubMed E-utilities only)

**Session 3 (Final):**
- Cards upgraded: 4 (093, 099, 101, 102)
- API cost: $0 (PubMed E-utilities only)
- Final extraction depth: 97% (99/102)

**Also completed:** Created what-is-obesity.md plain-language answer page and updated vault routing

## Summary

All 102 cancer source cards have been processed:
- 99 cards (97%) at abstract+ extraction depth
- 3 cards remain at partial (not PubMed indexed - expected)
- 1 duplicate identified (src-cancer-098 = src-cancer-091)
- 1 book review identified (src-cancer-099)

## Completed Additional Work

### Topic Pages Updated (2026-06-03)

| Page | New Claims | New Sources |
|------|------------|-------------|
| mammary-carcinoma.md | MC46-MC55 (10 claims) | 069, 081, 088, 090, 091, 093, 100, 101 |
| lymphoma.md | LY28-LY31 (4 claims) | 084, 086, 102 |
| oral-squamous-cell-carcinoma.md | OSCC26-OSCC32 (7 claims) | 071, 073, 074, 080 |

New subsections added:
- FMC: AKT/PTEN pathway, CXCR4/CXCL12 metastasis, TIL/TAM immune, targeted drug delivery
- Lymphoma: FeLV subgroups, horizontal transmission, age-dependent susceptibility
- OSCC: Podoplanin targeting, immune microenvironment, species-specific pathogenesis, MCT1/MCT4 inhibition

## Remaining Optional Work

1. Deep extraction on high-value papers (e.g., src-cancer-093 phosphoproteomics)
2. Further cross-referencing of findings across disease modules

---

**Handoff Status:** COMPLETE
**Extraction target achieved: 97% (exceeded 90% goal)**
